Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals — Technical Presentation (June 2024)

5 slides from Longboard Pharmaceuticals's technical presentation, Jun 10, 2024

  1. Slide 1: Bexicaserin (LP352) Open-Label Extension (OLE) Interim Analysis

    Exhibit 99.2 Bexicaserin (LP352) Open-Label Extension (OLE) Interim Analysis JUNE 10, 2024 1 LONGBOARD PHARMACEUTICALS

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation (including verbal statements that may accompany it) contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: bexicaserin’s (LP352) planned global Phase 3 program, data

  3. Slide 3: Summary: Interim Analysis from Bexicaserin (LP352) OLE Study

    Summary: Interim Analysis from Bexicaserin (LP352) OLE Study • 100% of PACIFIC completers continued into OLE (95.1% in OLE at 6-months) • PACIFIC completers n=41(DS=3, LGS=20, DEE Other=18) • Sustained response over an approximate 6- Overall OLE month treatment period n=40 • Favorable safety and tol

  4. Slide 4: Median Percent Seizure Reduction

    Bexicaserin (LP352) Median Observed Countable Motor Seizure Reduction in OLE Open-Label Extension* (6-Month Treatment Period) 20 Median Percent Seizure Reduction 0 from PACIFIC Baseline -20 -40 50% Reduction -60 Bexicaserin 201 / Transition to Bexicaserin OLE OLE dose -80 Placebo 201 / Bexicaserin O

  5. Slide 5: Summary: Bexicaserin (LP352) Safety and Tolerability in the OLE Interim Analysis

    Summary: Bexicaserin (LP352) Safety and Tolerability in the OLE Interim Analysis Overall (N = 41) Overall (N = 41) Parameter n (%) Preferred Term* n (%) Safety Set 41 (100) Upper respiratory tract infections 5 (12.2) Full Analysis Set 40 (97.6) COVID-19 3 (7.3) • SAEs in the overall group were compr

Longboard Pharmaceuticals — Technical Presentation (June 2024) on 6ix